Singapore, Dec. 12 -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, has announced the completion of a $108 million Series B financing round.

Proceeds from this financing will primarily support the planned global Phase III pivotal programme for the startup's lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination therapies for KRAS G12C-mutant cancers across key countries and regions, including the United States, China, and the European Union, to facilitate global regulatory submissions.

Furthermore, the funding will facilitate ongoing development of D3 Bio's comprehensive pipeline of targeted...